The 2024 American Diabetes Association (ADA) guidelines have recommendations for perioperative care in diabetes patients that include having a goal HbA1c of less than 8%, and to hold SGLT2 inhibitors at least three days before scheduled surgeries for canagliflozin, dapagliflozin, bexagliflozin, and empagliflozin, and four days for ertugliflozin [20]. This evidence concerns the gene SLC5A2 and diabetes mellitus.